<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556891</url>
  </required_header>
  <id_info>
    <org_study_id>111-3281</org_study_id>
    <nct_id>NCT03556891</nct_id>
  </id_info>
  <brief_title>Pivotal Study of eCoin for OAB With UUI</brief_title>
  <official_title>Pivotal Study of Subcutaneous Tibial Nerve Stimulation With eCoin for Overactive Bladder (OAB) With Urgency Urinary Incontinence (UUI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valencia Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valencia Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of
      eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency
      urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as
      measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy
      or 52 weeks of implantation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Anticipated">April 12, 2022</completion_date>
  <primary_completion_date type="Actual">April 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects experiencing 50% or better improvement in urgency urinary incontinence episodes as measured by a 3-day voiding diary.</measure>
    <time_frame>48 weeks after device activation.</time_frame>
    <description>Responder rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term safety in all patients. Incidence of device or implantation related adverse events.</measure>
    <time_frame>52 weeks after implantation.</time_frame>
    <description>All adverse events will be reported in all patients who were implanted 12 months after implantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Moderate-term safety in all patients. Incidence of device or implantation related adverse events.</measure>
    <time_frame>24 weeks after device activation</time_frame>
    <description>All adverse events will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate-term effectiveness data. Proportion of subjects experiencing 50% or better improvement in urgency urinary incontinence episodes as measured by a 3-day voiding diary.</measure>
    <time_frame>24 weeks after device activation</time_frame>
    <description>Moderate-term effectiveness data, responder rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing improvement in UUI episodes, urinary voids, urgent episodes, and nocturia as measured by a 3-day voiding diary. Patient reported outcomes as measured on the OABq, PGI-I, and patient satisfaction questionnaires.</measure>
    <time_frame>24 and 48 weeks after device activation</time_frame>
    <description>Improvement from baseline on secondary outcome measures relating to Frequency, Nocturia, Urgency and Satisfaction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urge Incontinence</condition>
  <condition>Incontinence, Urinary</condition>
  <condition>Urinary Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>eCoin Tibial Nerve Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eCoin Tibial Nerve Stimulation</intervention_name>
    <description>Subcutaneous stimulation of the tibial nerve using the eCoin device.</description>
    <arm_group_label>eCoin Tibial Nerve Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          1. Women and men between 18 and 80 years old.

          2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and
             stress incontinence with a predominant urgency component (selfreported), for at least
             6 months.

          3. Individual is without pharmacological treatment of overactive bladder (antimuscarinics
             and beta-3 agonists).

          4. Individual is intolerant of or has an inadequate response to any of anticholinergics,
             Î²3-adrenoceptor agonists, onabotulinumtoxinA, or percutaneous tibial nerve
             stimulation.

        Primary Exclusion Criteria:

          1. Predominant stress urinary incontinence with more than 1/3 stress urinary incontinent
             episodes when compared to total urinary incontinent episodes.

          2. Clinically significant bladder outlet obstruction.

          3. Clinically significant pelvic organ prolapse beyond the hymenal ring.

          4. Inadequate skin integrity or any evidence of an infection or inflammation in either
             lower leg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott MacDiarmid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alliance Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sequoia Urology Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SurgOne PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates of Norwalk</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Bladder Institute</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Medical Group</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UnityPoint Clinic</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Urology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Urology Specialists</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Female Pelvic Medicine &amp; Reconstructive Surgery (FPM Institute)</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina OB/GYN</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

